AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...

AbbVie Inc. (ABBV) is a global biopharmaceutical company, founded in 2013 as a spinoff from Abbott Laboratories, focusing on discovering and delivering innovative medicines and solutions for complex ...

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Shares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Warning! GuruFocus has detected 8 Warning Signs with ABBV. AbbVie Inc (NYSE:ABBV), a global biopharmaceutical powerhouse, has recently filed its 10-Q report on November 4, 2024. This SWOT analysis ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

Shares of AbbVie Inc. ABBV tumbled 12.57% to $174.43 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.10% to 6,001.35 ...